Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTP-026 in STEMI
2023-509182-21-00Phase 2Completed
- Sponsor
- ResoTher Pharma
- Start
- Sep 2024
- Modality
- Small Molecules, Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in acute ST-segment elevation myocardial infarction (STEMI) comparing RTP-026 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Cardiac injury biomarkers. Started Sep 2024; status: completed.
02
Drugs
RTP-026
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2023-509182-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509182-21-00.